SeaCrest Wealth Management LLC Makes New $57,000 Investment in Arvinas, Inc. (NASDAQ:ARVN)

SeaCrest Wealth Management LLC acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVNGet Rating) during the second quarter, Holdings Channel reports. The fund acquired 1,350 shares of the company’s stock, valued at approximately $57,000.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Arvinas by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 4,023,581 shares of the company’s stock valued at $270,786,000 after acquiring an additional 31,372 shares during the period. BlackRock Inc. boosted its stake in shares of Arvinas by 0.6% during the first quarter. BlackRock Inc. now owns 3,525,259 shares of the company’s stock valued at $237,251,000 after purchasing an additional 19,519 shares during the period. State Street Corp grew its holdings in shares of Arvinas by 7.1% in the first quarter. State Street Corp now owns 1,021,370 shares of the company’s stock worth $68,738,000 after purchasing an additional 67,431 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Arvinas by 22.6% in the first quarter. Wellington Management Group LLP now owns 776,569 shares of the company’s stock worth $52,263,000 after buying an additional 143,274 shares during the period. Finally, American Century Companies Inc. raised its holdings in Arvinas by 22.6% during the 1st quarter. American Century Companies Inc. now owns 617,606 shares of the company’s stock valued at $41,565,000 after buying an additional 114,020 shares during the last quarter. Hedge funds and other institutional investors own 91.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ARVN. Capital One Financial began coverage on shares of Arvinas in a report on Tuesday, October 25th. They issued an “overweight” rating on the stock. SVB Leerink reduced their price target on Arvinas from $91.00 to $89.00 and set an “outperform” rating on the stock in a report on Friday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Wednesday, September 21st. Barclays initiated coverage on Arvinas in a research note on Friday, September 9th. They set an “overweight” rating and a $90.00 target price on the stock. Finally, Credit Suisse Group raised their price target on Arvinas to $81.00 in a research note on Tuesday, November 15th. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $81.47.

Arvinas Stock Down 3.2 %

Shares of Arvinas stock opened at $51.31 on Friday. The company has a market cap of $2.73 billion, a P/E ratio of -10.78 and a beta of 1.89. Arvinas, Inc. has a 52-week low of $34.90 and a 52-week high of $84.96. The firm’s 50 day moving average price is $46.00 and its 200-day moving average price is $46.02.

About Arvinas

(Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Featured Stories

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVNGet Rating).

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.